Strategic partnerships Leverage Turbine’s validated collaborations with Bayer and AstraZeneca to identify co-selling or co-development opportunities, emphasizing joint research programs and expanded access to pharma pipelines.

Clinical translation advantage Position Turbine’s AI-driven virtual experiments as a way to de-risk early drug candidates and improve translatability, offering pharma partners faster progression to Phase II with higher predictive accuracy.

Broad enterprise reach Target large biopharma and biotech services buyers who could benefit from scalable virtual experimentation across multiple therapeutic areas, highlighting the platform’s billions of simulated trials and potential cost savings.

Funding credibility Highlight strong funding backing from Accel and MSD Global Health Innovation Fund to instill confidence in stability and long-term collaboration potential, easing partner investments and pilot commitments.

Proof of value Showcase the nearly 30 research programs already supported and measurable wins in reducing Phase II risk, using case studies to tailor sales pitches to specific therapeutic areas and patient-hit scenarios.